SG11201502317VA - Telomerase inhibitors for use in therapy - Google Patents

Telomerase inhibitors for use in therapy

Info

Publication number
SG11201502317VA
SG11201502317VA SG11201502317VA SG11201502317VA SG11201502317VA SG 11201502317V A SG11201502317V A SG 11201502317VA SG 11201502317V A SG11201502317V A SG 11201502317VA SG 11201502317V A SG11201502317V A SG 11201502317VA SG 11201502317V A SG11201502317V A SG 11201502317VA
Authority
SG
Singapore
Prior art keywords
therapy
telomerase inhibitors
telomerase
inhibitors
Prior art date
Application number
SG11201502317VA
Inventor
Vinay Tergaonkar
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201502317VA priority Critical patent/SG11201502317VA/en
Publication of SG11201502317VA publication Critical patent/SG11201502317VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201502317VA 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy SG11201502317VA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201502317VA SG11201502317VA (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012071023 2012-09-25
SG11201502317VA SG11201502317VA (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy
PCT/SG2013/000418 WO2014051519A1 (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy

Publications (1)

Publication Number Publication Date
SG11201502317VA true SG11201502317VA (en) 2015-05-28

Family

ID=50388738

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201702375RA SG10201702375RA (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy
SG11201502317VA SG11201502317VA (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201702375RA SG10201702375RA (en) 2012-09-25 2013-09-25 Telomerase inhibitors for use in therapy

Country Status (5)

Country Link
US (1) US20150232856A1 (en)
EP (1) EP2900229A4 (en)
CN (1) CN104797246A (en)
SG (2) SG10201702375RA (en)
WO (1) WO2014051519A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030763A (en) * 2015-06-16 2015-11-11 中国药科大学 Application of wedelolactone in preparing drug for resisting ulcerative colitis
CN108998415A (en) * 2018-07-09 2018-12-14 道赛尔生物科技（武汉）有限公司 The research method that wedelolactone is applied in preparation treatment lung cancer product
WO2020252195A1 (en) * 2019-06-11 2020-12-17 The Wistar Institute Of Anatomy And Biology Telomerase reverse transcriptase degraders and methods of use thereof
CN110804554B (en) * 2019-11-12 2023-05-12 南昌艾迪康医学检验实验室有限公司 Cell lysate and application thereof
CN111499694B (en) * 2020-06-17 2020-11-24 苏州拓维生物技术有限公司 Mammary cancer stem cell specific membrane-penetrating peptide and application thereof in preparation of composition interfering hTERT gene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249723A1 (en) * 2000-03-31 2001-10-15 Geron Corporation Telomerase inhibitor polynucleotides
US6435076B2 (en) * 2000-07-19 2002-08-20 Campbell Hausfeld/Scott Fetzer Cmopany Air compressor assembly with bearing pocket
US20020058077A1 (en) 2000-11-15 2002-05-16 National University Of Singapore Cancer chemotherapeutical and chemopreventive agent
US7897752B2 (en) * 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process

Also Published As

Publication number Publication date
US20150232856A1 (en) 2015-08-20
CN104797246A (en) 2015-07-22
SG10201702375RA (en) 2017-04-27
EP2900229A1 (en) 2015-08-05
EP2900229A4 (en) 2016-05-18
WO2014051519A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
HRP20171474T1 (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
EP3698782C0 (en) Carbamate compounds for use in therapy
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HK1203806A1 (en) Cold therapy device
PL2780332T3 (en) Morpholinylbenzotriazines for use in cancer therapy
IL238453A0 (en) Trans-clomiphene for use in cancer therapy
SG10201702375RA (en) Telomerase inhibitors for use in therapy
GB201207305D0 (en) Therapy
LT2872176T (en) Carboranylporphyrins for use in the treatment of cancer
SG11201404121TA (en) Device for cold therapy
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201206926D0 (en) Novel compositions having use in therapy
GB201102210D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102213D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy